Baird analyst on why he's skeptical about Gilead's Remdesivir clinical studies

Brian Skorney, Robert W. Baird analyst who covers Gilead Sciences, joins 'Closing Bell' to discuss why he's skeptical about Gilead Science's Remdesivir clinical studies to see if the drug can treat COVID-19.